Drägerwerk AG & Co. KGaA (DGWPF)
OTCMKTS
· Delayed Price · Currency is USD
55.81
-1.19 (-2.09%)
May 27, 2025, 4:00 PM EDT
Drägerwerk AG & Co. KGaA Revenue
Drägerwerk AG & Co. KGaA had revenue of 730.26M EUR in the quarter ending March 31, 2025, a decrease of -0.76%. This brings the company's revenue in the last twelve months to 3.37B, up 0.51% year-over-year. In the year 2024, Drägerwerk AG & Co. KGaA had annual revenue of 3.37B, down -0.08%.
Revenue (ttm)
3.37B EUR
Revenue Growth
+0.51%
P/S Ratio
0.35
Revenue / Employee
202.91K EUR
Employees
16,585
Market Cap
1.29B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.37B | -2.62M | -0.08% |
| Dec 31, 2023 | 3.37B | 328.28M | 10.78% |
| Dec 31, 2022 | 3.05B | -283.19M | -8.51% |
| Dec 31, 2021 | 3.33B | -77.86M | -2.29% |
| Dec 31, 2020 | 3.41B | 625.45M | 22.49% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
| American Oncology Network | 1.76B |
Drägerwerk AG & Co. KGaA News
- 4 weeks ago - Drägerwerk AG & Co KGaA (DGWPF) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Drägerwerk AG & Co KGaA (DGWPF) Full Year 2024 Earnings Call Transcript - Seeking Alpha